Active surveillance for favorable risk prostate cancer: Rationale, risks, and results

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 6, 2007, Pages 505-509

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Doubling time; Prostate cancer surveillance; PSA kinetics; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; COMORBIDITY; DISEASE COURSE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MALE; PATIENT IDENTIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 36348933946     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.021     Document Type: Review

References (17)

1. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150 (1993) 379-385
2. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
3. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from United States prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
4. Welch H.G., Schwartz L.M., and Woloshin S. PSA levels in the United States: Implications of various definitions of abnormal. JNCI 97 (2005) 1132-1137
5. Albertsen P., Hanley J.A., and Fine J. Twenty-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
6. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate Cancer and the Will Rogers Phenomenon. Natl Cancer Inst 97 (2005) 1248-1253
7. Klotz L. Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 175 (2004) 48-50
8. Klotz L. Active surveillance for prostate cancer: For whom?. J Clin Oncol 23 (2005) 8165-8169
9. Parker C. Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5 (2004) 101-106
10. Choo R., Klotz L., Danjoux C., et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 (2002) 1664-1669
11. Epstein J.I., Walsh P.C., and Carter H.B. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166 (2001) 1688-1691
12. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
13. Zhang L., Loblaw A., and Klotz L. Modeling PSA kinetics in patients on active surveillance. J Urol 176 (2006) 1392-1397
14. Bill-Axelson A., and Holmberg L. Radical prostatectomy vs. watchful waiting (update). N Engl J Med 352 (2005) 1977-1984
15. Parker C., Muston D., Melia J., et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94 (2006) 1361-1368
16. Pound C., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
17. U.S. Mortality Table, 2003; see Table 1 of this reference.